Re: growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Beckhardt
Stacey
S
D002227:Carbazoles / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005663:Furans; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D011355:Prodrugs / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D002227:Carbazoles; D004791:Enzyme Inhibitors; D005663:Furans; D007211:Indoles; D011355:Prodrugs; C119379:lestaurtinib; D011505:Protein-Tyrosine Kinases